Ibere Pharmaceuticals financial data

Industry
Blank Checks
Location
2005 Market Street, Suite 2030, Philadelphia, PA
State of incorporation
Cayman Islands
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 14, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 91 % -64.5%
Debt-to-equity -105 % +6.62%
Return On Equity -82.9 % -533%
Return On Assets 4.46 % +287%

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -1.04M USD -59.7%
Nonoperating Income (Expense) 7.22M USD -50%
Net Income (Loss) Attributable to Parent 6.19M USD +412%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.45K USD -99.3%
Assets, Current 113K USD -88.4%
Assets 139M USD -0.02%
Liabilities, Current 469K USD +61.4%
Liabilities 5.95M USD -51.1%
Retained Earnings (Accumulated Deficit) -5.83M USD +47.8%
Stockholders' Equity Attributable to Parent -5.83M USD +47.9%
Liabilities and Equity 139M USD -0.02%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -324K USD +27.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -324K USD -131%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.45K USD -99.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%